Evidence map›Paper›PMID 35982962›Full record

ArticleFrontiers in oncology2022

Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.

Ran You, Qingyu Xu, Qi Wang, Qingqiao Zhang, Weizhong Zhou, Chi Cao, Xiangzhong Huang, Honghai Ji, Penghua Lv, Hao Jiang and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 1 country.

Ran YouInterventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Qingyu XuInterventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Qi WangInterventional Radiology Department, The First People's Hospital of Changzhou, Changzhou, China.
Qingqiao ZhangDepartment of Obstetrics and Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Weizhong ZhouInterventional Radiology Department, Jiangsu Province Hospital, Nanjing, China.
Chi CaoInterventional Radiology Department, Xuzhou Central Hospital, Xuzhou, China.
Xiangzhong HuangInterventional Radiology Department, Jiangyin People's Hospital, Jiangyin, China.
Honghai JiInterventional Radiology Department, Yancheng No. 1 People's Hospital, Yancheng, China.
Penghua LvInterventional Radiology Department, The Northern Jiangsu People's Hospital, Yangzhou, China.
Hao JiangInterventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
You LuInterventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Yong JinInterventional Radiology Department, The Second Affiliated Hospital of SooChow University, Suzhou, China.
Yongjun LiInterventional Radiology Department, Nantong Tumor Hospital, Nantong, China.
Long ChengInterventional Radiology Department, Xuzhou Central Hospital, Xuzhou, China.
Weidong WangInterventional Radiology Department, Wuxi People's Hospital, Wuxi, China.
Hao XuDepartment of Obstetrics and Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xiaoli ZhuInterventional Radiology Department, The First Affiliated Hospital of SooChow University, Suzhou, China.
Guowen YinInterventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNJiangsu Cancer Hospital · CNSoochow University · CNXuzhou Central Hospital · CNXuzhou Medical College · CNJiangsu Province Hospital · CNJiangyin People's Hospital · CNNantong Tumor Hospital · CNNantong University · CNNorthern Jiangsu People's Hospital · CNThe First People's Hospital of Changzhou · CNWuxi People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Camrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study evaluated the efficacy and safety of camrelizumab plus transarterial chemoembolization (TACE) in treating intermediate-to-advanced HCC patients. Methods: This study consecutively enrolled 101 intermediate to advanced HCC patients. All patients received camrelizumab-based treatment within 30 days of the perioperative period of the TACE operation. The primary outcome was progression-free survival (PFS), and the secondary effects were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and AEs. Results: Specifically, the median PFS was 9.7 (95% confidence interval: 7.4-12.0) months, with a 1-year PFS rate of 30.6%. Meanwhile, the median OS was not reached (NR) yet, with a 1-year OS rate of 61.9%. Besides, the CR, PR, SD, and PD rates were 12.8%, 44.9%, 29.5%, and 12.8%, respectively. The ORR and DCR were 57.7% and 87.2%, respectively. More cycles of camrelizumab were independently correlated with prolonged PFS (hazard ratio (HR): 0.415, Conclusion: The camrelizumab plus TACE regimen is effective and safe, indicating its potential to serve as a promising treatment choice for intermediate to advanced HCC patients.

Indexed as

adverse eventcamrelizumabhepatocellular carcinomasurvivaltransarterial chemoembolization

Identifiers

PMID35982962
PMCPMC9378838
OpenAlexW4289522150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.